{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:30:48Z","timestamp":1793334648950,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012431","name":"Celldex Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaci.2026.08.019","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:59:42Z","timestamp":1788537582000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barzolvolimab blocks stem cell factor\u2013enhanced IgE activation without inducing apoptosis in KITD816V mast cells"],"prefix":"10.1016","author":[{"given":"Mengjie","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Scheffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Frischbutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-2900","authenticated-orcid":false,"given":"Polina","family":"Pyatilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.08.019_bib1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.iac.2023.04.011","article-title":"World Health Organization classification and diagnosis of mastocytosis: update 2023 and future perspectives","volume":"43","author":"Valent","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2026.08.019_bib2","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","article-title":"Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM","volume":"12","author":"Valent","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.08.019_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2014.06.031","article-title":"Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood","volume":"135","author":"Broesby-Olsen","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2015-07-655100","article-title":"KIT D816V\u2013mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression","volume":"127","author":"Garcia-Montero","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.019_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.anai.2021.07.014","article-title":"Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders","volume":"127","author":"Munoz-Gonzalez","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib6","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1182\/blood.2025029507","article-title":"Improved diagnostic screening and classification of clonal mast cell diseases by ultrasensitive KIT p.D816V detection","volume":"146","author":"Navarro-Navarro","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.019_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene","volume":"100","author":"Yavuz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.019_bib8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.019_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.iac.2006.05.006","article-title":"Systemic mastocytosis: clinical manifestations and differential diagnosis","volume":"26","author":"Butterfield","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2026.08.019_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/joim.12410","article-title":"Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease","volume":"279","author":"G\u00fclen","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.jaci.2026.08.019_bib11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/all.13425","article-title":"Development and validation of the mastocytosis activity score","volume":"73","author":"Siebenhaar","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/all.12842","article-title":"Development and validation of the mastocytosis quality of life questionnaire: MC-QoL","volume":"71","author":"Siebenhaar","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaip.2024.08.034","article-title":"Mast cell disorders and Hymenoptera venom\u2013triggered anaphylaxis: evaluation and management","volume":"13","author":"Boggs","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.08.019_bib14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/j.1398-9995.2005.00963.x","article-title":"Diagnosis of Hymenoptera venom allergy","volume":"60","author":"Bil\u00f3","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/17843286.2022.2137631","article-title":"Mastocytosis and related entities: a practical roadmap","volume":"78","author":"Beyens","year":"2023","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jaci.2026.08.019_bib16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib17","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2014.01.012","article-title":"Treatment strategies in mastocytosis","volume":"34","author":"Siebenhaar","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaci.2026.08.019_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2026.04.001","article-title":"Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years","author":"Akin","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2026.101352","article-title":"Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis","volume":"19","author":"Pongdee","year":"2026","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2026.08.019_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2026.02.025","article-title":"Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: results from the randomized, phase 2, interventional PIONEER study","author":"Siebenhaar","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2026.08.019_bib21","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2026.08.019_bib22","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaci.2026.08.019_bib23","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/all.15585","article-title":"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria","volume":"78","author":"Terhorst-Molawi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib25","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/all.16598","article-title":"Anti-KIT barzolvolimab for chronic spontaneous urticaria","volume":"80","author":"Maurer","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000048188","article-title":"Mastocytosis: mediator-related signs and symptoms","volume":"127","author":"Castells","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/all.12126","article-title":"Mast cell activation syndromes: definition and classification","volume":"68","author":"Valent","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.08.019_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2026.103975","article-title":"CRISPR\/Cas9 engineered and whole-genome characterized KIT D816V-mutant human iPSC lines","volume":"93","author":"Luo","year":"2026","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.jaci.2026.08.019_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102406","article-title":"ASSURED-optimized CRISPR protocol for knockout\/SNP knockin in hiPSCs","volume":"4","author":"Ludwik","year":"2023","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jaci.2026.08.019_bib30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jaci.2021.07.027","article-title":"A novel approach for studying mast cell\u2013driven disorders: mast cells derived from induced pluripotent stem cells","volume":"149","author":"Luo","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jim.2014.07.003","article-title":"A novel method to generate and culture human mast cells: peripheral CD34+ stem cell\u2013derived mast cells (PSCMCs)","volume":"413","author":"Schmetzer","year":"2014","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jaci.2026.08.019_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-0716-0696-4_5","article-title":"Generation and culture of peripheral CD34+ stem cell\u2013derived mast cells (PSCMCs)","volume":"2163","author":"Luo","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jaci.2026.08.019_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaci.2026.08.019_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1939-1676.2006.tb02871.x","article-title":"Comparison of four staining methods for detection of mast cells in equine bronchoalveolar lavage fluid","volume":"20","author":"Leclere","year":"2006","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jaci.2026.08.019_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-4939-1568-2_19","article-title":"Assay of mast cell mediators","volume":"1220","author":"R\u00e5dinger","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jaci.2026.08.019_bib36","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.4049\/jimmunol.1202323","article-title":"The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis","volume":"191","author":"Kraft","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2567.2003.01559.x","article-title":"Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene","volume":"108","author":"Sundstr\u00f6m","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2026.08.019_bib38","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.019_bib39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jaci.2016.01.017","article-title":"Repeated Fc\u03b5RI triggering reveals modified mast cell function related to chronic allergic responses in tissue","volume":"138","author":"Suurmond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.08.019_bib40","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and Fc\u03b5RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.08.019_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2003-08-2769","article-title":"NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation","volume":"104","author":"Tkaczyk","year":"2004","journal-title":"Blood"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926006287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:38:37Z","timestamp":1793331517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926006287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S0091674926006287"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.08.019","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barzolvolimab blocks stem cell factor\u2013enhanced IgE activation without inducing apoptosis in KITD816V mast cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}